EBMT Cell Therapy MED-A Manual

This document contains information on how to complete the Cell Therapy MED-A data collection form.


EBMT Cell Therapy MED-A Manual - cover page
Brand
EBMT
Category
Health Care
Document type
User Manual
Language
English
Pages
22
File format
PDF
File size
1.4 MB
Published
18 October, 2023
Updated
18 October, 2023
MD5 checksum
59A1D969FCE6AA59D89DCE2C1DE0FEC8

About this manual

This manual explains how to complete the EBMT Cell Therapy MED-A form, which collects data on cell therapies including T-lymphocytes, CAR-T cells, and other advanced therapies. It covers registration timing, patient follow-up, and form submission requirements.

The form is divided into sections for Day 0 registration, Day 100 follow-up, and combined 6-month/annual follow-up. It applies to centers performing cell therapy, not referral or follow-up-only centers. Forms must be submitted as close to the treatment date as possible, with specific rules for multiple infusions or changes in indication.

What's inside

  • Introduction
  • Cell Therapy Registry
  • Instructions
  • Identification
  • Indication for Treatment
  • Cell Therapy Treatment
  • Donor
  • Cell Therapy Infusion Unit (CTIU)
  • Treatment
  • Cell Infusion Episode

Frequently asked questions

When should the Cell Therapy MED-A form be submitted?

The Day 0 registration form should be submitted as close to the date of cell therapy as possible. Remaining forms should be recorded at their specific timepoints (at day 100, 6 months, 1 year after the cell therapy and then annually) or at time of death, whichever occurs first.

How many Cell Therapy MED-A forms should be submitted for multiple infusions?

For therapy with cell infusions distributed across several days, overall lasting more than 100 days and given for the same indication, submit one form per 100-day interval, starting with the first infusion episode within each interval.

What types of cell therapies does this form cover?

The form covers stem cells, progenitors or mature cells, such as T-lymphocytes, sorted, cultured and/or genetically manipulated, whether hematopoietic or non-hematopoietic, including CAR-T cells and other advanced therapeutic medicinal products (ATMP).

Download PDF (1.4 MB)